A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Latest Information Update: 06 Feb 2023
At a glance
- Drugs VB 201 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 31 Jan 2023 Status changed from recruiting to completed.
- 02 Feb 2021 New trial record
- 27 Jan 2021 According to a VBL Therapeutics media release, it announced the dosing of the first patient in this study.